Anabolic and anticatabolic agents in critical care

Mile Stanojcic, Celeste Finnerty, Marc G. Jeschke

Research output: Contribution to journalReview article

10 Citations (Scopus)

Abstract

Profound metabolic derangements occur in critically ill patients; this hypermetabolic response is a major contributor to adverse outcomes. Despite the pharmacological therapies currently available to counteract this devastating cascade, future studies are warranted to explore new multimodality agents that will counteract these effects while maintaining glycemic control and preventing unfavorable complications.

Original languageEnglish (US)
Pages (from-to)325-331
Number of pages7
JournalCurrent Opinion in Critical Care
Volume22
Issue number4
DOIs
StatePublished - Aug 1 2016

Fingerprint

Anabolic Agents
Critical Care
Critical Illness
Pharmacology
Therapeutics

Keywords

  • anabolic
  • anticatabolic
  • burns
  • critical illness
  • hypermetabolism
  • insulin
  • metformin
  • oxandrolone
  • propranolol

ASJC Scopus subject areas

  • Critical Care and Intensive Care Medicine

Cite this

Anabolic and anticatabolic agents in critical care. / Stanojcic, Mile; Finnerty, Celeste; Jeschke, Marc G.

In: Current Opinion in Critical Care, Vol. 22, No. 4, 01.08.2016, p. 325-331.

Research output: Contribution to journalReview article

Stanojcic, Mile ; Finnerty, Celeste ; Jeschke, Marc G. / Anabolic and anticatabolic agents in critical care. In: Current Opinion in Critical Care. 2016 ; Vol. 22, No. 4. pp. 325-331.
@article{5db633cd632041fe9408006d5806c3ef,
title = "Anabolic and anticatabolic agents in critical care",
abstract = "Profound metabolic derangements occur in critically ill patients; this hypermetabolic response is a major contributor to adverse outcomes. Despite the pharmacological therapies currently available to counteract this devastating cascade, future studies are warranted to explore new multimodality agents that will counteract these effects while maintaining glycemic control and preventing unfavorable complications.",
keywords = "anabolic, anticatabolic, burns, critical illness, hypermetabolism, insulin, metformin, oxandrolone, propranolol",
author = "Mile Stanojcic and Celeste Finnerty and Jeschke, {Marc G.}",
year = "2016",
month = "8",
day = "1",
doi = "10.1097/MCC.0000000000000330",
language = "English (US)",
volume = "22",
pages = "325--331",
journal = "Current Opinion in Critical Care",
issn = "1070-5295",
publisher = "Lippincott Williams and Wilkins",
number = "4",

}

TY - JOUR

T1 - Anabolic and anticatabolic agents in critical care

AU - Stanojcic, Mile

AU - Finnerty, Celeste

AU - Jeschke, Marc G.

PY - 2016/8/1

Y1 - 2016/8/1

N2 - Profound metabolic derangements occur in critically ill patients; this hypermetabolic response is a major contributor to adverse outcomes. Despite the pharmacological therapies currently available to counteract this devastating cascade, future studies are warranted to explore new multimodality agents that will counteract these effects while maintaining glycemic control and preventing unfavorable complications.

AB - Profound metabolic derangements occur in critically ill patients; this hypermetabolic response is a major contributor to adverse outcomes. Despite the pharmacological therapies currently available to counteract this devastating cascade, future studies are warranted to explore new multimodality agents that will counteract these effects while maintaining glycemic control and preventing unfavorable complications.

KW - anabolic

KW - anticatabolic

KW - burns

KW - critical illness

KW - hypermetabolism

KW - insulin

KW - metformin

KW - oxandrolone

KW - propranolol

UR - http://www.scopus.com/inward/record.url?scp=84973392560&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84973392560&partnerID=8YFLogxK

U2 - 10.1097/MCC.0000000000000330

DO - 10.1097/MCC.0000000000000330

M3 - Review article

VL - 22

SP - 325

EP - 331

JO - Current Opinion in Critical Care

JF - Current Opinion in Critical Care

SN - 1070-5295

IS - 4

ER -